ArticleNarra J2025
Seroepidemiological investigation of SARS-CoV-2 infection and risk factors in Indonesia before mass COVID-19 vaccination.
Article in Narra J, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Respiratory syncytial virus disease burden in adults aged ≥50 years old: A retrospective national surveillance database analysis in Mexico (2015-2023).Human vaccines & immunotherapeutics · 2026Article
- Molecular screening for active severe acute respiratory syndrome coronavirus 2 infections among non-human primates in Indonesia.The Journal of veterinary medical science · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At the onset of the coronavirus disease 2019 (COVID-19) pandemic in Indonesia, surveillance focused on finding and treating symptomatic cases. However, emerging evidence indicated that asymptomatic and pre-symptomatic individuals significantly contributed to viral transmission. This highlights the need for comprehensive surveillance to understand better the actual spread of SARS-CoV-2. Therefore, the aim of this study was to determine the seroprevalence of SARS-CoV-2 antibodies in the general population across Indonesia and identify risk factors associated with infection at the beginning of the pandemic. A cross-sectional survey was conducted across 17 provinces, 69 districts/cities, and 1,020 villages in Indonesia from December 22, 2020, to February 15, 2021. A multistage random sampling technique was employed. Serological testing using enzyme-linked immunosorbent assay (ELISA) was performed to detect anti-SARS-CoV-2. Complex sample analysis, adjusted for weights, was utilized to estimate the national seroprevalence and a generalized linear model with a binomial distribution was applied to identify risk factors. A total of 10,161 individuals were included in the final analysis, with the national seroprevalence being 14.8% (95% confidence interval (CI): 14.2-18.5). The prevalence was higher in females (16.8%; 95%CI: 12.5-22.3), individuals aged 46-59 years (18.6%; 95%CI: 14.2-24.0), and in urban areas (20.1%; 95%CI: 15.0-26.2). The highest prevalence was observed in North Maluku (35.6%; 95%CI: 29.3-42.5). Notably, 54.2% of seropositive individuals were asymptomatic, while 7.5% reported hypertension as a comorbidity. Factors associated with higher seroprevalence were being married (adjusted prevalence ratio (aPR): 1.47; 95%CI: 1.02-2.12), widow (aPR: 1.74; 95%CI: 1.01-3.00), and close contact with confirmed cases (aPR: 2.04; 95%CI: 1.52-2.73). This study revealed a COVID-19 prevalence significantly higher than official estimate in Indonesia, underscoring the need for improved surveillance system to more accurately track disease spread and to inform timely public health responses in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.